Moderate evidence suggests that using medical marijuana can benefit chemotherapy-induced nausea and vomiting (CINV), as well as anorexia, and educating patients about the appropriate use of medical marijuana can maximize outcomes, according to a review presented by Lisa M. Holle, PharmD, BCOP, FHOPA, Associate Clinical Professor at UConn School of Pharmacy, and Associate Professor at UConn School of Medicine, presented at the 2019 HOPA Annual Conference.
Tetrahydrocannabinol (THC) is the primary component of cannabis and acts as weak partial agonist on CB1 and CB2 receptors. The psychoactive component can affect pain, appetite, digestion, emotions, thought processes, and depending on dose and patient tolerance, it can result in adverse events. The use of THC is viable for a myriad of symptoms and conditions including pain, nausea, muscle spasms, appetite stimulation, anxiety, depression, and post-traumatic stress disorder (PTSD). Conversely, cannabidiol (CBD)